TG Therapeutics
TGTX
106 hedge funds and large institutions have $345M invested in TG Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
65% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 26
9% more funds holding
Funds holding: 97 → 106 (+9)
1% more call options, than puts
Call options by funds: $5.15M | Put options by funds: $5.11M
4% less capital invested
Capital invested by funds: $359M → $345M (-$13.6M)
2.68% less ownership
Funds ownership: 54.11% → 51.43% (-2.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21.6M |
| 2 |
BlackRock
New York
|
+$5.94M |
| 3 |
AG
Artal Group
Luxembourg
|
+$5.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.47M |
| 5 |
CCI
Columbus Circle Investors
|
+$4.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$8.15M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$4.81M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$1.91M |
| 4 |
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
|
-$1.87M |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | -$22.9K | -2,044 | -88% |
|
|
MAM
102
Meeder Asset Management
Dublin,
Ohio
| $3K | – | – | – |
|
|
KF
103
Krilogy Financial
St. Louis,
Missouri
| $3K | +$3.36K | +300 | New |
|
|
GEA
104
Glen Eagle Advisors
Kingston,
New Jersey
| $1K | +$1.12K | +100 | New |
|
|
AF
105
Allworth Financial
Folsom,
California
| $1K | – | – | – |
|
|
DM
106
Deerfield Management
New York
| – | -$8.15M | -700,000 | Closed |
|
|
TRSOTSOK
107
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
| – | -$1.87M | -160,700 | Closed |
|
108
Two Sigma Investments
New York
| – | -$1.24M | -106,274 | Closed |
|
109
Goldman Sachs
New York
| – | -$501K | -43,020 | Closed |
|
110
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$443K | -38,000 | Closed |
|
|
TSS
111
Two Sigma Securities
New York
| – | -$325K | -27,906 | Closed |
|
|
PAG
112
Private Advisory Group
Redmond,
Washington
| – | -$240K | -20,659 | Closed |
|
113
Janus Henderson Group
London,
United Kingdom
| – | -$10K | -844 | Closed |
|
|
FMA
114
FNY Managed Accounts
New York
| – | -$2K | -252 | Closed |
|
TGTX Hedge Fund Activity: Q2 2017 in Review
106 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2017, worth a combined $345M — down 3.8% from $359M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TGTX positions and 9 closed out — a net gain of 10 holders — while 43 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $21.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $8.15M sold.
- 106 institutional investors held TG Therapeutics (TGTX) as of Q2 2017, up from 97 in Q1 2017.
- Funds reported $345M of TG Therapeutics stock for Q2 2017, down 3.8% quarter-over-quarter.
- 19 funds opened new TG Therapeutics positions in Q2 2017 and 9 closed out, a net change of +10 holders.
- The largest TG Therapeutics buyer in Q2 2017 was State Street, an estimated $21.6M added.
- The largest TG Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $8.15M sold.
Based on aggregated 13F filings for Q2 2017.